Short Term Price Target on EXACT Sciences Corporation (EXAS)

EXACT Sciences Corporation (NASDAQ:EXAS) : The highest level EXACT Sciences Corporation (NASDAQ:EXAS) is projected to reach is $18 for the short term and the lowest estimate is at $7. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $11.83 and the possibility the share price can swing is $3.81.

Shares of Exact Sciences Corporation rose by 10.46% in the last five trading days and 83.38% for the last 4 weeks. Exact Sciences Corporation is up 76.01% in the last 3-month period. Year-to-Date the stock performance stands at 32.72%. Also, In the latest statement by the brokerage house, Craig-Hallum upgrades its outlook on EXACT Sciences Corporation (NASDAQ:EXAS). The current rating of the shares is Buy, according to the research report released by the firm. Previously, the company had a rating of Hold. The brokerage firm raises the price target at $18 per share. The rating by the firm was issued on June 16, 2016.

EXACT Sciences Corporation (NASDAQ:EXAS) : Zacks Investment Research ranks EXACT Sciences Corporation (NASDAQ:EXAS) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 2, which indicates as a Buy.

EXACT Sciences Corporation (NASDAQ:EXAS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.25 and $11.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $13.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $12.25, notching a gain of 8.50% for the day. The total traded volume was 10,531,423 . The stock had closed at $11.29 on the previous day.

In an insider trading activity, The officer (SVP and General Counsel), of Exact Sciences Corp, Coward D Scott had unloaded 1,685 shares at $6.62 per share in a transaction on April 1, 2016. The total value of transaction was $11,155. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.